- Home
- NBIS vs AXSM Comparison
NBIS vs AXSM Comparison
Compare NBIS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIS
- AXSM
- Stock Information
- Founded
- NBIS 2000
- AXSM 2012
- Country
- NBIS Netherlands
- AXSM United States
- Employees
- NBIS N/A
- AXSM N/A
- Industry
- NBIS
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- NBIS
- AXSM Health Care
- Exchange
- NBIS NYSE
- AXSM Nasdaq
- Market Cap
- NBIS 4.8B
- AXSM 5.1B
- IPO Year
- NBIS 2011
- AXSM 2015
- Fundamental
- Price
- NBIS $35.79
- AXSM $107.22
- Analyst Decision
- NBIS Strong Buy
- AXSM Strong Buy
- Analyst Count
- NBIS 3
- AXSM 15
- Target Price
- NBIS $41.33
- AXSM $170.20
- AVG Volume (30 Days)
- NBIS 7.7M
- AXSM 650.4K
- Earning Date
- NBIS 02-20-2025
- AXSM 05-05-2025
- Dividend Yield
- NBIS N/A
- AXSM N/A
- EPS Growth
- NBIS N/A
- AXSM N/A
- EPS
- NBIS N/A
- AXSM N/A
- Revenue
- NBIS $117,500,000.00
- AXSM $432,157,000.00
- Revenue This Year
- NBIS $42,672.77
- AXSM $62.62
- Revenue Next Year
- NBIS N/A
- AXSM $62.94
- P/E Ratio
- NBIS N/A
- AXSM N/A
- Revenue Growth
- NBIS 462.20
- AXSM 72.16
- 52 Week Low
- NBIS $14.09
- AXSM $64.11
- 52 Week High
- NBIS $50.87
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- NBIS N/A
- AXSM 47.24
- Support Level
- NBIS N/A
- AXSM $103.02
- Resistance Level
- NBIS N/A
- AXSM $110.95
- Average True Range (ATR)
- NBIS 0.00
- AXSM 4.11
- MACD
- NBIS 0.00
- AXSM -0.17
- Stochastic Oscillator
- NBIS 0.00
- AXSM 24.74
About NBIS NEBIUS GROUP N V
Nebius Group NV is a tech company. It is a European provider of infrastructure and services to AI builders globally. The group builds full-stack infrastructure to service the growth of the AI industry, including the scale of GPU clusters, cloud platforms, tools, and services for developers. It has R&D hubs across Europe, North America and Israel.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.